- Home
- ZDGE vs KLRS Comparison
ZDGE vs KLRS Comparison
Compare ZDGE & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- KLRS
- Stock Information
- Founded
- ZDGE 2008
- KLRS 2019
- Country
- ZDGE United States
- KLRS United States
- Employees
- ZDGE N/A
- KLRS N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZDGE Technology
- KLRS Health Care
- Exchange
- ZDGE Nasdaq
- KLRS Nasdaq
- Market Cap
- ZDGE 39.9M
- KLRS 46.0M
- IPO Year
- ZDGE N/A
- KLRS N/A
- Fundamental
- Price
- ZDGE $3.09
- KLRS $3.89
- Analyst Decision
- ZDGE
- KLRS Strong Buy
- Analyst Count
- ZDGE 0
- KLRS 2
- Target Price
- ZDGE N/A
- KLRS $23.00
- AVG Volume (30 Days)
- ZDGE 40.5K
- KLRS 689.3K
- Earning Date
- ZDGE 10-28-2025
- KLRS 08-13-2025
- Dividend Yield
- ZDGE N/A
- KLRS N/A
- EPS Growth
- ZDGE N/A
- KLRS N/A
- EPS
- ZDGE N/A
- KLRS N/A
- Revenue
- ZDGE $29,511,000.00
- KLRS N/A
- Revenue This Year
- ZDGE N/A
- KLRS N/A
- Revenue Next Year
- ZDGE $2.95
- KLRS N/A
- P/E Ratio
- ZDGE N/A
- KLRS N/A
- Revenue Growth
- ZDGE 1.27
- KLRS N/A
- 52 Week Low
- ZDGE $1.73
- KLRS $2.14
- 52 Week High
- ZDGE $4.89
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ZDGE 44.78
- KLRS 57.01
- Support Level
- ZDGE $2.91
- KLRS $2.37
- Resistance Level
- ZDGE $3.25
- KLRS $4.90
- Average True Range (ATR)
- ZDGE 0.15
- KLRS 0.67
- MACD
- ZDGE 0.03
- KLRS 0.04
- Stochastic Oscillator
- ZDGE 57.89
- KLRS 29.20
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.